Results 261 to 270 of about 3,125,328 (279)

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Signal Transduction and Targeted Therapy, 2023
Hong-Hong Yan, Ying Cheng
exaly  

TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.

Drug resistance updates
Wenjie Huang, Xiaojun Hu, Xiang He, Dongyue Pan, Zhaorong Huang, Zhanfeng Gu, Guobing Huang, Ping Wang, Chunhui Cui, Yingfang Fan   +9 more
semanticscholar   +1 more source

KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer

Oncogene, 2021
Yaoyi Xiong, Lingao Ju, Lushun Yuan, Liang Chen, Gang Wang, Huimin Xu, Tianchen Peng, Yongwen Luo, Yu Xiao, Xinghuan Wang   +9 more
semanticscholar   +1 more source

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology, 2007
Steven Gallinger
exaly  

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Journal of Clinical Oncology, 2008
Giorgio Scagliotti, Johan Filip Vansteenkiste, Digumarti Raghunadha Rao   +2 more
exaly  

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Lancet Oncology, The, 2014
Yi-Long Wu, Shun Lu, Yunchao Huang
exaly  

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Lancet, The, 2016
Katshuhiko Uesaka, Narikazu Boku, Yukiyasu Okamura   +2 more
exaly  

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Lancet, The, 2016
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky   +2 more
exaly  

In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy

Science Translational Medicine, 2018
Chao Wang, Jinqiang Wang, Xudong Zhang
exaly  

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

New England Journal of Medicine, 2013
Daniel D Von Hoff, E Gabriela Chiorean, Reni Michele   +2 more
exaly